Effects of short-term and chronic olanzapine treatment on immediate early gene protein and tyrosine hydroxylase immunoreactivity in the rat locus coeruleus and medial prefrontal cortex

Neuroscience

Volumn 143, Issue 2, 2006, Pages 573-585

  Verma, V ^a   Rasmussen, K ^b   Dawe, G S ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

antipsychotic agents; genes; immediate early; locus coeruleus; prefrontal cortex; tyrosine 3 monooxygenase

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 2; EARLY GROWTH RESPONSE FACTOR 1; EARLY GROWTH RESPONSE FACTOR 2; IMMEDIATE EARLY PROTEIN; OLANZAPINE; PROTEIN; PROTEIN C FOS; PROTEIN C JUN; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; DRUG EFFECT; DRUG EFFICACY; IMMUNOREACTIVITY; LOCUS CERULEUS; MALE; NONHUMAN; OSMOTIC MINIPUMP; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; TREATMENT DURATION; UPREGULATION;

ANALYSIS OF VARIANCE; ANIMALS; BENZODIAZEPINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ENZYME-LINKED IMMUNOSORBENT ASSAY; IMMEDIATE-EARLY PROTEINS; IMMUNOHISTOCHEMISTRY; LOCUS COERULEUS; MALE; PREFRONTAL CORTEX; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN UPTAKE INHIBITORS; TIME FACTORS; TYROSINE 3-MONOOXYGENASE;

EID: 33750816490     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2006.08.010     Document Type: Article

References (72)

1. Agid O., Kapur S., Arenovich T., and Zipursky R.B. Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. Arch Gen Psychiatry 60 (2003) 1228-1235
2. Ananth J., Burgoyne K.S., Gadasalli R., and Aquino S. How do the atypical antipsychotics work?. J Psychiatry Neurosci 26 (2001) 385-394
3. Arvanitogiannis A., Tzschentke T.M., Riscaldino L., Wise R.A., and Shizgal P. Fos expression following self-stimulation of the medial prefrontal cortex. Behav Brain Res 107 (2000) 123-132
4. Bergstrom R.F., Callaghan J.T., Cerimele B.J., Kurtz D.L., and Hatcher B.L. Population pharmacokinetics and plasma concentrations of olanzapine. In: Tran P.V., Bymaster F.P., Tye N., Herrara J.M., Breier A., and Tollefson G.D. (Eds). Olanzapine (Zyprexa): A novel antipsychotic (2000), Lippincott Williams & Wilkins, Philadelphia 232-252
5. Bing G., Stone E.A., Zhang Y., and Filer D. Immunohistochemical studies of noradrenergic-induced expression of c-fos in the rat CNS. Brain Res 592 (1992) 57-62
6. Bing G.Y., Filer D., Miller J.C., and Stone E.A. Noradrenergic activation of immediate early genes in rat cerebral cortex. Brain Res Mol Brain Res 11 (1991) 43-46
7. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72 (1976) 248-254
8. Bunney W.E., and Bunney B.G. Evidence for a compromised dorsolateral prefrontal cortical parallel circuit in schizophrenia. Brain Res Brain Res Rev 31 (2000) 138-146
9. Callicott J.H., Mattay V.S., Bertolino A., Finn K., Coppola R., Frank J.A., Goldberg T.E., and Weinberger D.R. Physiological characteristics of capacity constraints in working memory as revealed by functional MRI. Cereb Cortex 9 (1999) 20-26
10. Callicott J.H., and Weinberger D.R. Neuropsychiatric dynamics: the study of mental illness using functional magnetic resonance imaging. Eur J Radiol 30 (1999) 95-104
11. Craine J.E., Hall E.S., and Kaufman S. The isolation and characterization of dihydropteridine reductase from sheep liver. J Biol Chem 247 (1972) 6082-6091
12. Dalley J.W., Cardinal R.N., and Robbins T.W. Prefrontal executive and cognitive functions in rodents: neural and neurochemical substrates. Neurosci Biobehav Rev 28 (2004) 771-784
13. Dawe G.S., Huff K.D., Vandergriff J.L., Sharp T., O'Neill M.J., and Rasmussen K. Olanzapine activates the rat locus coeruleus: in vivo electrophysiology and c-Fos immunoreactivity. Biol Psychiatry 50 (2001) 510-520
14. Derijard B., Hibi M., Wu I.H., Barrett T., Su B., Deng T., Karin M., and Davis R.J. JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain. Cell 76 (1994) 1025-1037
15. Deutch A.Y., and Duman R.S. The effects of antipsychotic drugs on Fos protein expression in the prefrontal cortex: cellular localization and pharmacological characterization. Neuroscience 70 (1996) 377-389
16. Dinan T.G., and Aston-Jones G. Acute haloperidol increases impulse activity of brain noradrenergic neurons. Brain Res 307 (1984) 359-362
17. Dinan T.G., and Aston-Jones G. Chronic haloperidol inactivates brain noradrenergic neurons. Brain Res 325 (1985) 385-388
18. Dragunow M., and Faull R. The use of c-fos as a metabolic marker in neuronal pathway tracing. J Neurosci Methods 29 (1989) 261-265
19. Dumas S., Javoy-Agid F., Hirsch E., Agid Y., and Mallet J. Tyrosine hydroxylase gene expression in human ventral mesencephalon: detection of tyrosine hydroxylase messenger RNA in neurites. J Neurosci Res 25 (1990) 569-575
20. Fadda F., Gessa G.L., Marcou M., Mosca E., and Rossetti Z. Evidence for dopamine autoreceptors in mesocortical dopamine neurons. Brain Res 293 (1984) 67-72
21. Gius D., Cao X.M., Rauscher III F.J., Cohen D.R., Curran T., and Sukhatme V.P. Transcriptional activation and repression by Fos are independent functions: the C terminus represses immediate-early gene expression via CArG elements. Mol Cell Biol 10 (1990) 4243-4255
22. Goldman-Rakic P.S. Regional and cellular fractionation of working memory. Proc Natl Acad Sci U S A 93 (1996) 13473-13480
23. Goldman-Rakic P.S. The physiological approach: functional architecture of working memory and disordered cognition in schizophrenia. Biol Psychiatry 46 (1999) 650-661
24. Goldman-Rakic P.S., and Selemon L.D. Functional and anatomical aspects of prefrontal pathology in schizophrenia. Schizophr Bull 23 (1997) 437-458
25. Gronier B.S., and Rasmussen K. Electrophysiological effects of acute and chronic olanzapine and fluoxetine in the rat prefrontal cortex. Neurosci Lett 349 (2003) 196-200
26. Guo Z., Du X., and Iacovitti L. Regulation of tyrosine hydroxylase gene expression during transdifferentiation of striatal neurons: changes in transcription factors binding the AP-1 site. J Neurosci 18 (1998) 8163-8174
27. Hebert M.A., Serova L.I., and Sabban E.L. Single and repeated immobilization stress differentially trigger induction and phosphorylation of several transcription factors and mitogen-activated protein kinases in the rat locus coeruleus. J Neurochem 95 (2005) 484-498
28. Herdegen T., and Leah J.D. Inducible and constitutive transcription factors in the mammalian nervous system: control of gene expression by Jun, Fos and Krox, and CREB/ATF proteins. Brain Res Brain Res Rev 28 (1998) 370-490
29. Howard-Jones N. A CIOMS ethical code for animal experimentation. WHO Chronicle 39 (1985) 51-56
30. Kapur S., Arenovich T., Agid O., Zipursky R., Lindborg S., and Jones B. Evidence for onset of antipsychotic effects within the first 24 hours of treatment. Am J Psychiatry 162 (2005) 939-946
31. Kapur S., VanderSpek S.C., Brownlee B.A., and Nobrega J.N. Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy. J Pharmacol Exp Ther 305 (2003) 625-631
32. Kasper S., and Resinger E. Cognitive effects and antipsychotic treatment. Psychoneuroendocrinology 28 Suppl 1 (2003) 27-38
33. Kvetnansky R., and Sabban E.L. Stress and molecular biology of neurotransmitter-related enzymes. Ann N Y Acad Sci 851 (1998) 342-356
34. Li X.M., Perry K.W., Wong D.T., and Bymaster F.P. Olanzapine increases in vivo dopamine and norepinephrine release in rat prefrontal cortex, nucleus accumbens and striatum. Psychopharmacology (Berl) 136 (1998) 153-161
35. Melia K.R., and Duman R.S. Involvement of corticotropin-releasing factor in chronic stress regulation of the brain noradrenergic system. Proc Natl Acad Sci U S A 88 (1991) 8382-8386
36. Meltzer H.Y., and McGurk S.R. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull 25 (1999) 233-255
37. Mitchell S.N., Smith K.M., Joseph M.H., and Gray J.A. Increases in tyrosine hydroxylase messenger RNA in the locus coeruleus after a single dose of nicotine are followed by time-dependent increases in enzyme activity and noradrenaline release. Neuroscience 56 (1993) 989-997
38. Mize R.R. Quantitative image analysis for immunocytochemistry and in situ hybridization. J Neurosci Methods 54 (1994) 219-237
39. Morgan J.I., and Curran T. Stimulus-transcription coupling in the nervous system: involvement of the inducible proto-oncogenes fos and jun. Annu Rev Neurosci 14 (1991) 421-451
40. Nagy J.I., Price M.L., Staines W.A., Lynn B.D., and Granholm A.C. The hyaluronan receptor RHAMM in noradrenergic fibers contributes to axon growth capacity of locus coeruleus neurons in an intraocular transplant model. Neuroscience 86 (1998) 241-255
41. Nilsson L.K., Schwieler L., Engberg G., Linderholm K.R., and Erhardt S. Activation of noradrenergic locus coeruleus neurons by clozapine and haloperidol: involvement of glutamatergic mechanisms. Int J Neuropsychopharmacol 8 (2005) 329-339
42. Ohashi K., Hamamura T., Lee Y., Fujiwara Y., and Kuroda S. Propranolol attenuates haloperidol-induced Fos expression in discrete regions of rat brain: possible brain regions responsible for akathisia. Brain Res 802 (1998) 134-140
43. Ohashi K., Hamamura T., Lee Y., Fujiwara Y., Suzuki H., and Kuroda S. Clozapine- and olanzapine-induced Fos expression in the rat medial prefrontal cortex is mediated by beta-adrenoceptors. Neuropsychopharmacology 23 (2000) 162-169
44. Ordway G.A., and Szebeni K. Effect of repeated treatment with olanzapine or olanzapine plus fluoxetine on tyrosine hydroxylase in the rat locus coeruleus. Int J Neuropsychopharmacol 7 (2004) 321-327
45. Osterhout C.A., Sterling C.R., Chikaraishi D.M., and Tank A.W. Induction of tyrosine hydroxylase in the locus coeruleus of transgenic mice in response to stress or nicotine treatment: lack of activation of tyrosine hydroxylase promoter activity. J Neurochem 94 (2005) 731-741
46. Otani S. Prefrontal cortex function, quasi-physiological stimuli, and synaptic plasticity. J Physiol Paris 97 (2003) 423-430
47. Paxinos G., and Watson C. The rat brain in stereotaxic coordinates (1997), Academic Press, Sydney
48. Pudovkina O.L., Kawahara Y., de Vries J., and Westerink B.H. The release of noradrenaline in the locus coeruleus and prefrontal cortex studied with dual-probe microdialysis. Brain Res 906 (2001) 38-45
49. Robbins T.W. Dissociating executive functions of the prefrontal cortex. Philos Trans R Soc Lond B Biol Sci 351 (1996) 1463-1470
50. Robertson G.S., and Fibiger H.C. Neuroleptics increase c-fos expression in the forebrain: contrasting effects of haloperidol and clozapine. Neuroscience 46 (1992) 315-328
51. Robertson GS, Fibiger HC (Effects of olanzapine on regional C-Fos expression in rat forebrain. Neuropsychopharmacology 14:105-110.
52. Robertson G.S., Matsumura H., and Fibiger H.C. Induction patterns of Fos-like immunoreactivity in the forebrain as predictors of atypical antipsychotic activity. J Pharmacol Exp Ther 271 (1994) 1058-1066
53. Sabban E.L., Hebert M.A., Liu X., Nankova B., and Serova L. Differential effects of stress on gene transcription factors in catecholaminergic systems. Ann N Y Acad Sci 1032 (2004) 130-140
54. Sagar S.M., Sharp F.R., and Curran T. Expression of c-fos protein in brain: metabolic mapping at the cellular level. Science 240 (1988) 1328-1331
55. Seager M.A., Barth V.N., Phebus L.A., and Rasmussen K. Chronic coadministration of olanzapine and fluoxetine activates locus coeruleus neurons in rats: implications for bipolar disorder. Psychopharmacology (Berl) 181 (2005) 126-133
56. Seager M.A., Huff K.D., Barth V.N., Phebus L.A., and Rasmussen K. Fluoxetine administration potentiates the effect of olanzapine on locus coeruleus neuronal activity. Biol Psychiatry 55 (2004) 1103-1109
57. Sebens J.B., Koch T., Ter Horst G.J., and Korf J. Olanzapine-induced Fos expression in the rat forebrain: cross-tolerance with haloperidol and clozapine. Eur J Pharmacol 353 (1998) 13-21
58. Serova L.I., Nankova B.B., Feng Z., Hong J.S., Hutt M., and Sabban E.L. Heightened transcription for enzymes involved in norepinephrine biosynthesis in the rat locus coeruleus by immobilization stress. Biol Psychiatry 45 (1999) 853-862
59. Shiman R., Akino M., and Kaufman S. Solubilization and partial purification of tyrosine hydroxylase from bovine adrenal medulla. J Biol Chem 246 (1971) 1330-1340
60. Smith K.M., Mitchell S.N., and Joseph M.H. Effects of chronic and subchronic nicotine on tyrosine hydroxylase activity in noradrenergic and dopaminergic neurones in the rat brain. J Neurochem 57 (1991) 1750-1756
61. Smith M.A., Brady L.S., Glowa J., Gold P.W., and Herkenham M. Effects of stress and adrenalectomy on tyrosine hydroxylase mRNA levels in the locus ceruleus by in situ hybridization. Brain Res 544 (1991) 26-32
62. Staiger J.F., Bisler S., Schleicher A., Gass P., Stehle J.H., and Zilles K. Exploration of a novel environment leads to the expression of inducible transcription factors in barrel-related columns. Neuroscience 99 (2000) 7-16
63. Stone E.A., and Zhang Y. Adrenoceptor antagonists block c-fos response to stress in the mouse brain. Brain Res 694 (1995) 279-286
64. Stone E.A., Zhang Y., and Carr K.D. Massive activation of c-fos in forebrain after mechanical stimulation of the locus coeruleus. Brain Res Bull 36 (1995) 77-80
65. Sun B., Chen X., Xu L., Sterling C., and Tank A.W. Chronic nicotine treatment leads to induction of tyrosine hydroxylase in locus ceruleus neurons: the role of transcriptional activation. Mol Pharmacol 66 (2004) 1011-1021
66. Suzuki T., Yamakuni T., Hagiwara M., and Ichinose H. Identification of ATF-2 as a transcriptional regulator for the tyrosine hydroxylase gene. J Biol Chem 277 (2002) 40768-40774
67. Tandon R., and Jibson M.D. Efficacy of newer generation antipsychotics in the treatment of schizophrenia. Psychoneuroendocrinology 28 Suppl 1 (2003) 9-26
68. van Dam H., Wilhelm D., Herr I., Steffen A., Herrlich P., and Angel P. ATF-2 is preferentially activated by stress-activated protein kinases to mediate c-jun induction in response to genotoxic agents. EMBO J 14 (1995) 1798-1811
69. van Gaalen M., Kawahara H., Kawahara Y., and Westerink B.H. The locus coeruleus noradrenergic system in the rat brain studied by dual-probe microdialysis. Brain Res 763 (1997) 56-62
70. Weinberger D.R., Egan M.F., Bertolino A., Callicott J.H., Mattay V.S., Lipska B.K., Berman K.F., and Goldberg T.E. Prefrontal neurons and the genetics of schizophrenia. Biol Psychiatry 50 (2001) 825-844
71. Westerink B.H., de Boer P., de Vries J.B., Kruse C.G., and Long S.K. Antipsychotic drugs induce similar effects on the release of dopamine and noradrenaline in the medial prefrontal cortex of the rat brain. Eur J Pharmacol 361 (1998) 27-33
72. Zigmond R.E., Schon F., and Iversen L.L. Increased tyrosine hydroxylase activity in the locus coeruleus of rat brain stem after reserpine treatment and cold stress. Brain Res 70 (1974) 547-552